Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New upgrade: Journal your trades with more detail

Trevi Therapeutics, Inc.

Contributing Author

Recent Articles by Trevi Therapeutics, Inc.

Aug-06	Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates TRVI GlobeNewswire
Aug-06	Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates TRVI GlobeNewswire
Jul-30	Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 TRVI GlobeNewswire
Jul-28	Trevi Therapeutics to Participate in Upcoming August Conferences TRVI GlobeNewswire
Jun-17	Trevi Therapeutics Announces Upcoming June and July Event Schedule TRVI +6.30% GlobeNewswire
May-05	Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates TRVI GlobeNewswire
Apr-30	Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference TRVI GlobeNewswire
Apr-28	Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 TRVI GlobeNewswire
Apr-23	Trevi Therapeutics to Participate in Upcoming May Events TRVI GlobeNewswire
Apr-20	Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares TRVI TRVI -5.06% GlobeNewswire
Apr-16	Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock TRVI GlobeNewswire
Apr-16	Trevi Therapeutics Announces Proposed Public Offering of Common Stock TRVI GlobeNewswire
Apr-01	Trevi Therapeutics to Participate in Upcoming Events TRVI GlobeNewswire
Mar-17	Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates TRVI GlobeNewswire
Mar-10	Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 TRVI GlobeNewswire
Mar-09	Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough TRVI -12.03% GlobeNewswire
Mar-02	Trevi Therapeutics to Participate in Upcoming March Conferences TRVI +5.45% GlobeNewswire
Feb-17	Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference TRVI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)